Cell Context Is the Third Axis of Synergy for the Combination of ATR Inhibition and Cisplatin in Ewing Sarcoma.

Jennifer Jess Kathleen M Sorensen Elissa A Boguslawski Matthew C Stout Zachary B Madaj Benjamin P Caiello Monica Pomaville Elizabeth R Wilson Seneca S Kinn-Gurzo Curtis C Parker Sridhar M Veluvolu Taylor V Brysgel Rebecca S Kaufman Susan M Kitchen-Goosen Jenna M Gedminas Patrick J Grohar

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)

These data exploit EWS-FLI1 driven alterations in cell context to broaden the therapeutic window of berzosertib and cisplatin to establish a promising combination therapy and a novel in vivo schedule. See related commentary by Ohmura and Grünewald, p. 3358.

Keyphrases

combination therapy
single cell
cell therapy
electronic health record
big data
oxidative stress